

<!-- page 1 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2019'02'11
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 11.02.2019
1A
w;s úfYI
wxl 2110$2 - 2019 fmnrjdß ui 11 jeks i÷od - 2019'02'11
No. 2110/2  -  MONDAY,  FEBRUARY  11,  2019
EXTRAORDINARY
Y%S ,xld m%cd;dka;%sl iudcjd§ ckrcfha .eiÜ m;%h
The Gazette of the Democratic Socialist Republic of Sri Lanka
(Published by Authority)
PART I : SECTION (I) — GENERAL
Government  Notifications
                  
       
              
               
            
        
                  
     
         
             
         
               
            
               
               
            
               
        
                 
        
              
               
            
         
                  
CONVENTION   AGAINST  DOPING  IN   SPORTS  ACT,   No.  33   OF  2013
REGULATIONS made by the Minister of  Sports under Section 34 read with Section 3 of the Convention against Doping
in Sport  Act, No. 33 of 2013.
HARIN F ERNANDO,
Minister of Telecommunication,
Foreign Employment and Sports.
Colombo,
25th January, 2019.
Regulations
1. These regulations may be cited as the Anti-Doping (Prohibited List) Regulations  No. 04 of 2018.
2. These regulations shall be deemed to have come into  operation on  1
st, January 2019.
THE   WORLD   ANTI-DOPING   CODE
THE   2019 P ROHIBITED LIST
INTERNATIONAL STANDARD
The Official text of the Prohibited List  shall be maintained by W ADA and shall be published in English and
French. In the event of any conflict between the English and French versions,  the English  version shall prevail.
This List shall come into effect on 01 st  January, 2019.
The 2019 prohibited List
2018 September.
This Gazette Extraordinary can be downloaded from www.documents.gov.lk
1A - G  28939 — 107 (01/2019)

<!-- page 2 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2019'02'11
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 11.02.2019
2A
THE  WORLD    ANTI-DOPING    CODE
INTERNATIONAL STANDARD
PROHIBITED    LIST
JANUARY 2019
This List shall come into effect on 01 st January 2019
IN ACCORDANCE WITH ARTICLE  4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES
SHALL  BE CONSIDERED  AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4,  S4.5,
S6.A, AND PROHIBITED METHODS  M1, M2 AND M3
SUBSTANCES    AND    METHODS    PROHIBITED    AT    ALL   TIMES
(IN-AND  OUT-OF-COMPETITION)
PROHIBITED    SUBSTANCES
S0-NON-APPROVED   SUBSTANCES
Any pharmacological substance which is not addressed  by any of the subsequent sections of the List and with no current
approval by any governmental  regulatory health authority for human therapeutic use ( e.g. drugs under pre-clinical or
clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all
times.
S1.   ANABOLIC   AGENTS
Anabolic agents are prohibited.
1. ANABOLIC  ANDROGENIC  STEROIDS (AAS)
a. Exogenous*  AAS,  including:
1- Androstenediol  
(5-androst-1-ene-317-diol); 1-Androstenedione (5-androst-1-ene-3,17-dione); 1-Androsterone (3-
-hydroxy-5-androst-1-ene-17-one); 1-Testosterone [ -hydroxy-5-androst-1-en-3-one]; Bolasterone; Calusterone; Clostebol;
Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 -ol); Dehydrochlormethyltestosterone (4-chloro- -hydroxy- -
methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone  ( -methyl-5-androst-2-en--ol and -methyl-5-androst-3-en-
-ol ; Drostanolone  ; Ethylestrenol  (19-norpregna-4-en- -ol); Fluoxymesterone;  Formebolone; Furazabol  ( -
methyl[1,2,5]oxadiazolo[3',4':2,3]-5 -androstan- -ol); Gestrinone; Mestanolone, Mesterolone, Metandienone ; ( -hydroxy-
17-methylandrosta-1,4-dien-3-one); Metenolone; Methandriol; Methasterone  ( -hydroxy-2 ,17-dimethyl-5 -androstan-3-
one); Methyldienolone (-hydroxy-17-methylestra-4,9-dien-3-one);  Methyl-1-testosterone ( -hydroxy-17,methyl-5-androst-
1-en-3-one); Methylnortestosterone  (-hydroxy-17 -methylestr-4-en-3 one) ; Methyltestosterone; Metribolone
(methyltrienolone,-hydroxy-17-methylestra-4,9,11-trien-3-one); Mibolerone;  Norboletone  ; Norclostebol; Norethandrolone;
Oxabolone; Oxandrolone ; Oxymesterone; Oxymetholone; Prostanozol  ( -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-
5-androstane); Quinbolone; Stanozolol; Stenbolone; Tetrahydrogestrinone ( -hydroxy-18a-homo-19-nor-17 -pregna-4,9,11-trien-
3-one); Trenbolone  ( -hydroxyestr-4,9,11-trien-3-one); and  other substances with a similar chemical structure or similar biological
effect (s).
b. Endogenous** AAS  when administered exogenously :
4-Androstenediol (androst-4-ene-3 17-diol); 4-Hydroxytestosterone ( -hydroxyandrost-4-en-3-one ) ;5- Adrostenedione
(androst-5-ene-317-dione) ; 7 -Hydroxy-DHEA; 7 -Hydroxy-DHEA;7-Keto-DHEA ;19-Norandrostenediol (estr-4-ene-3  17-diol)
; 19-Norandrostenedione (estr-4-ene-3  17-dione) ;  Androstanolone , (5-dihydrotestosterone, -hydroxy-5-androstan-3-one) ;
Androstenediol (androst-5-ene-3 17-diol);  Androstenedione, (androst-4-ene-3,17-dione); Boldenone; Boldione (androsta-1, 4-
diene-3, 17-dione); Epiandrosterone (3 -Hydroxy-5 -androstan-17-one); Epi-dihydrostestoterone (17 -hydroxy-5 -androstan-3-

<!-- page 3 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2019'02'11
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 11.02.2019
3A
one); Epitestosterone ;Nandrolone (19-nortestosterone); Prasterone  (dehydroepiandrosterone, DHEA,3 -hydroxyandrost-5-en-17-
one);  Testosterone; and their metabolites and  isomers, when administered exogenously including but not limited to:
  2. OTHER   ANABOLIC   AGENTS
Including, but not limited to:
Clenbuterol, selective androgen receptor modulators  (SARMs; e.g. andarine LGD-4033, enobosarm (ostarine) and
RAD 140), Tibolone, Zeranol and Zilpaterol.
For purposes of this section:
* “exogenous” refers to a substance which is not ordinarily  produced by the body naturally.
** “endogenous” refers to a substance which is  ordinarily  produced by the body naturally.
S2. PEPTIDE  HORMONES,   GROWTH     FACTORS,   RELATED    SUBSTANCES   AND   MIMETICS
The following substances, and other substances with similar chemical structure or similar  biological effect(s), are
prohibited:
1. Erythropoietin [EPO] - and agents affecting erythropoiesis, including but not limited to :
1.1. Er ythropoietin - Receptor Agonists , e. g.
Darbepoietins (dEPO); Erythropoietins (EPO) ; EPO based constructs [e. g. EPO-Fc, methoxy polyethylene
glycol -epoetin beta [CERA]] ;EPO mimetic agents and their constructs, [e.g. CNTO 530 and peginesatide] ;
1.2 Hypoxia - inducible factor (HIF) activating agents e.g. Argon ; Cobalt ; Daprodustat (GSK 1278863)
Molidustat (BAY 85-3934) ; Roxadustat  [FG-4592]; Vadadustat (AKB-6548) ; Xenon
1.3 GATA inhibitors, e. g. K-11706
1.4 TGF - beta [TGF -
] inhibitors, e.g. ; Luspatercept ; Sotatercept
1.5 Innate repair receptor agonists, e. g.
Asialo EPO ;
Carbamylated EPO [CEPO].
2. Peptide Hormones and their releasing factors.
2.1 Chorionic Gonadotrophin [CG[ and Luteinizing  Hormone (LH) and their releasing factors in males, e.g.
Buserelin,  deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin ;
2.2 Corticotrophins and their releasing factors, e. g. Corticorelin ;
2.3 Growth Hormone  [GH[ its fragments and releasing factors, including but not limited to :
Growth Hormone fragments, e. g. AOD - 9604 and hGH 176-191 ;
Growth Hormone Releasing Hormone [GHRH] and its analogues, e. g. CJC - 1293, CJC - 1295,
sermorelin and tesamorelin ;
Growth Hormone Secretagogues  [GHS[, e. g. lenomorelin (ghrelin) and its mimetics, e. g. anamorelin,
ipamorelin, macimorelin and tabimorelin ;
GH - Releasing Peptides  (GHRPs), e.g. alexamorelin,  GHRP - 1, GHRP - 2 [pralmoralin], GHRP - 3,
GHRP - 4, GHRP - 5, GHRP - 6 and examorelin [hexarelin].

<!-- page 4 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2019'02'11
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 11.02.2019
4A
3. Growth Factors and Growth Factor Modulators, including but not limited to ;
Fibroblast Growth Factors  (FGFs); Hepatocyte Growth Factor  (HGF); Insulin-like Growth Factor - 1
(IGF-1)  and its analogues; Mechano Growth Factors  (MGFs); Platelet-Derived Growth Factor  (PDGF);
Thymosin - 4 and its derivatives e. g. TB - 500 ; Vascular-Endothelial Growth Factor  (VEGF) and
other growth factors or growth modulators affecting muscle, tendon or ligament protein synthesis/degradation,
vascularisation, energy utilization, regenerative capacity, or fibre type switching.
S3. BETA - 2 AGONISTS
All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.
Including, but not limited to :
Fenoterol ; Formoterol ; Higenamine ; Indacaterol ; Olodaterol ; Procaterol ; Reproterol ; Salbutamol ; Salmeterol ;
Terbutaline ; Tretoquinol (trimetoquinol) Vilanterol ;
Except :
* Inhaled salbutamol : maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms
over 12 hours starting from any dose ;
* Inhaled formoterol : maximum delivered dose of 54  micrograms over 24 hours ;
* Inhaled salmeterol  : maximum 200 micrograms over 24 hours.
The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40ng/mL is not consistent with
therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete
proves, through  a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by
inhalation) up to the maximum indicated above.
S4.   HORMONE   AND   METABOLIC   MODULATORS
The following hormone and metabolic modulators are prohibited:
1. Aromatase inhibitors including, but not limited to: 2-Androstenol (5
-androst 2-en-17-ol) ; 2-Androstenone
(5-androst 2-en-17-one) ; 3-Androstenol (5 -androst 3-en-17-ol) ; 3-Androstenone (5 -androst 3-en-
17-one) ; 4-Androstene-3, 6, 17 trione (6-oxo) ; Aminoglutethimide; Anastrozole; Androsta - 1,4,6,-triene-
3,17-dione  (androstatrienedione);  Androsta-3,5-diene-7, 17-dione  (arimistane); Exemestane; Formestane;
Letrozole;  Testolactone.
2. Selective estrogen receptor modulators (SERMs) including, but not limited to : Raloxifene; Tamoxifen ;  Toremifene.
3. Other anti-estrogenic substances  including, but not limited to: Clomifene; Cyclofenil and Fulvestrant .
4. Agents preventing activin receptor IIB activation including, but not limited, to :
Activin A - neutralizing antibodies ; Activin receptor IIB competitors such as ; Decoy activin receptors (e. g.
ACE - 031) ; Anti-activin receptor IIB antibodies ( e. g. bimagrumab) ; Myostatin inhibitors such as : Agents
reducing or ablating myostatin expression ; Myostatin - binding proteins ( e. g. follistatin, myostatin propetide) ;
Mayostatin - neutralizing antibodies ( e. g. domagrozumab, landogrozumab, stamulumab)
5. Metabolic  modulators:
5.1 Activators of the AMP-activated protein kinase (AMPK) e.g. AICAR SR9009 ; and Peroxisome Proliferator
Activated Receptor  (PPAR)  agonists, e.g. 2-[2-methyl-4-[[4-methyl-2-[4-[trifluoromethyl] phenyl] thiazol-5-yl]
methylthio] phenoxyl] acetic acid [GW1516, GW501516] ;

<!-- page 5 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2019'02'11
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 11.02.2019
5A
5.2 Insulins and Insulin - Mimetics ;
5.3 Meldonium ;
5.4 Trimetazidine.
S5. DIURETICS    AND   MASKING    AGENTS
The following  diuretics, and masking agents are prohibited, as are other substances with a similar chemical structure or
similar biological effect (s)
Including, but not limited to:
* Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran,
hydroxyethyl starch and mannitol.
* Acetazolamide; amiloride;  bumetanide; canrenone; chlortalidone;  etacrynic acid; furosemide; indapamide;
metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide;
triamterene and vaptans, e.g. tolvaptan.
Except:
Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors
(e.g. dorzolamide, brinzolamide) ;
Local administration of felypressin in dental anesthesia.
The detection in an Athlete’s Sample at all times or In -Competition, as applicable, of any quantity of the following
substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine,
in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the
Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the
diuretic or masking agent.
PROHIBITED   METHODS
M1.  MANIPULATION    OF    BLOOD   AND   BLOOD    COMPONENTS
The following  are prohibited:
1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous
blood, or red blood cell products of any origin into the circulatory system.
2. Artificially enhancing the uptake, transport or delivery of  oxygen.
Including, but not limited to:
Perfluorochemicals; efaproxiral (RSR 13) and modified  haemoglobin products, e.g. haemoglobin-based blood
substitutes and microencapsulated haemoglobin  products, excluding supplemental oxygen by inhalation.
3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

<!-- page 6 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2019'02'11
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 11.02.2019
6A
M2.  CHEMICAL    AND   PHYSICAL    MANIPULATION
The following are prohibited:
1. Tampering, or Attempting to Tamper, to alter the integrity and  validity of Samples collected during Doping Control.
Including, but not limited to:
Urine substitution and/or adulteration, e.g. proteases.
2. Intravenous infusions and /or injections of more than a total of 100mL per 12 hour period except for those legitimately
received in the course of hospital treatments, surgical procedures or clinical investigations.
M3.  GENE  DOPING  AND  ALL  DOPING
The following with the potential to enhance sport performance, are prohibited:
1. The transfer of ploymers of nucleic acids  or nucleic acid analogues;
2. The use of gene editing agents designed to alter genome sequences and/or the transcripional or epigenetic
regulation of gene expression.
3. The use of normal or genetically modified cells.
SUBSTANCES   AND    METHODS
PROHIBITED IN- COMPETITION
IN ADDITION TO  THE  CLASSES  S0 TO  S5  AND M1  TO  M3  DEFINED  ABOVE,
THE   FOLLOWING  CLASSES  ARE  PROHIBITED  IN - COMPETITION:
PROHIBITED    SUBSTANCES
S6. STIMULANTS
All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited.
Stimulants include:
(a) Non- Specified Stimulants :
Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan;
Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam
[4- phenylpiracetam (carphedon)] ; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine
( d-) ; p- methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine and Prolintane.
A stimulant not expressly  listed in this section is a Specified Substance.
b. Specified Stimulants.
Including, but not limited to:
3-Methylhexan-2-amine (1, 2-dimethylpentylamine); 4-Methylhexan-2-amine (methylhexaneamine); 4-Methylpentan-
2-amine (1, 3-dimethylbutylamine); 5-Methylhexan-2-amine (1,4-dimethylpentylamine) ; Benzfetamine; Cathine**;
Cathinone and its analogues, e.g. mephedrone, methedrone, and   -pyrrolidinovalerophenone; Dimetamfetamine
(dimethylamphetamine); Ephedrine ***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine;  Etilefrine;
Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene;
Levmetamfetamine;  Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***;  Methylphenidate;
Nikethamide, Norfenefrine; Octopamine; Oxilofrine (methylsynephrine) ; Pemoline; Pentetrazol; Phenethylamine and

<!-- page 7 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2019'02'11
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 11.02.2019
7A
its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine;   Pseudoephedrine*****; Selegiline; Sibutramine;
Strychnine; Tenamfetamine (methylenedioxyamphetamine), Tuaminoheptane;  and other substances with a similar chemical
structure or similar biological effect(s).
Except:
* Clonidine
* Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2019 monitoring Program*.
* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine; These substances
are included in the 2019 monitoring Program, and are not considered Prohibited Substances .
** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.
*** Ephedrine and methylephedrine:  Prohibited when the concentration of either in urine is greater than 10
micrograms per milliliter.
**** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration
with local anaesthetic agents.
***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.
S7. NARCOTICS
The following narcotics are Prohibited:
Buprenorphine; Dextromoramide;  Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone;
Morphine; Nicomorphine ; Oxycodone; Oxymorphone; Pentazocine;  Pethidine.
S8. CANNABINOIDS
The following cannabinoids are Prohibited:
* Natural cannabinoids, e.g. cannabis, hashish and marijuana, synthetic cannabinoids e.g.
   9 - tetrahydrocannabinol (THC) and other caanabimimetics
Except
   * Cannabidiol
S9. GLUCOCORTICOIDS
All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.
including not not limited to :
Betamethasone; Budesonide ; Cortisone ; Deflazacort; Dexamethasone ; Fluticasone; Hydrocortisone;
Methylprednisolone; Prednisolone; Prednisone ; Triamcinolone
P1. BETA - BLOCKERS
Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition
where indicated
Archery (WA)*
Automobile (FIA)
Billiards (all disciplines) (WCBS)
Darts (WDF)
Golf (IGF)

<!-- page 8 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2019'02'11
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 11.02.2019
8A
Shooting (ISSF, IPC)*
Skiing/Snowboarding (FIS) in ski Jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air.
Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without
fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight
apnoea.
* Also prohibited Out-of-Competition
Including, but not limited to :
Acebutolol ; Alprenolol ; Atenolol ; Betaxolol ; Bisoprolol ; Bunolol ; Carteolol ; Carvedilol ; Celiprolol ; Esmolol ;
Labetalol ; Levobunolol ; Metipranolol ; Metoprolol ; Nadolol ; Oxprenolol ; Pindolol ; Propranolol ; Sotalol
Timolol.
THE  2019  MONITORING   PROGRAMME
The following substances are placed on the 2019 Monitoring Program :
1. Stimulants : In-competition only : Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradol
and synephrine
2. Narcotics : In-competition only : Codeine, hydrocodone and tramadol.
3. Glucocorticoids : In-competition (by routes of administration other than oral, intravenous, intramuscular or
rectal) and Out-of-competition (all routes of administration).
4. 2-ethylsulfanyl-1H-benzimidazole (bemitil)  : In-and Out-of Competition
5. Beta-2-agonists : In- and Out-of-Competition : any combination of beta-2-agonists.
02 -354
PRINTED AT THE DEPARTMENT OF GOVERNMENT PRINTING, SRI LANKA.